IR Conference Call for 2025 Q4 and Annual Earnings


  • IR conference call for 2025 Q4 and annual (preliminary) earnings release
  • Date: 2026-02-06 10:30, via conference call
  • Includes R&D session; materials posted on website and live audio webcasting
ADVERTISEMENT (250px+)

KOSPI Filing Information


  • Filing: Corporate Briefing (IR) Holding (Notice Disclosure)
  • Company: SK Biopharmaceuticals (326030)
  • Submission: SK Biopharmaceuticals Co., Ltd.
  • Receipt: 02-03-2026
  • Under KRX KOSPI Market Division